HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carmen Calle Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

7/2015Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
11/2014Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carmen Calle Research Topics

Disease

2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
07/2015 - 11/2014
1Inappropriate ADH Syndrome (SIADH)
09/2017
1Multiple Myeloma
09/2011
1Cellulitis
03/2005

Drug/Important Bio-Agent (IBA)

2Tyrosine Kinase InhibitorsIBA
07/2015 - 11/2014
1Bortezomib (Velcade)FDA Link
09/2017
1Vasopressins (Vasopressin)IBA
09/2017
1Imatinib Mesylate (Gleevec)FDA Link
07/2015
1Lenalidomide (CC 5013)FDA Link
09/2011
1Anti-Bacterial Agents (Antibiotics)IBA
03/2005

Therapy/Procedure

2Therapeutics
11/2014 - 03/2005